IP Verse

Pharmaceutical Formulations - EP4070787

The patent EP4070787 was granted to Gilead Sciences on Mar 1, 2023. The application was originally filed on Jun 29, 2016 under application number EP22176524A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4070787

GILEAD SCIENCES
Application Number
EP22176524A
Filing Date
Jun 29, 2016
Status
Granted And Under Opposition
Jan 27, 2023
Publication Date
Mar 1, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ZENTIVANov 29, 2023REDDIE & GROSEADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO0208241
DESCRIPTIONWO03016306
DESCRIPTIONWO2013025788
OPPOSITIONEP1583542
OPPOSITIONUS2007077295
OPPOSITIONWO2013025788
SEARCHWO2013116720
SEARCHWO2015022351
SEARCHWO2015196116

Non-Patent Literature (NPL) Citations (6) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- S.M. BERGE et al., J. Pharma Sci., (19770000), vol. 66, no. 1, pages 1 - 19
OPPOSITION- Anonymous, "Study Details | Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants ", ClinicalTrials.gov NCT01815736, (20150330), pages 1 - 8, ClinicalTrials.gov NCT01815736, URL: https://clinicaltrials.gov/study/NCT01815736, (20231130), XP093107511
OPPOSITION- Anonymous, " Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naive Adults NCT01797445", ClinicalTrials.gov, (20150116), pages 1 - 22, XP093107501
OPPOSITION- Richard J. Bastin, Michael J. Bowker, and Bryan J. Slater, "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities", Organic Process Research & Development, American Chemical Society, US, US , (20000719), vol. 4, no. 5, doi:10.1021/op000018u, ISSN 1083-6160, pages 427 - 435, XP008154792
OPPOSITION- Ruane Peter J., Dejesus Edwin, Berger Daniel, Markowitz Martin, Bredeek U. Fritz, Callebaut Christian, Zhong Lijie, Ramanathan Srini, S. Rhee Martin, Fordyce Marshall W., Yale Kitty, "Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1-Positive Adults", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, LIPPINCOTT WILLIAMS AND WILKINS,PHILADELPHIA, PA, US, US , (20130801), vol. 63, no. 4, doi:10.1097/QAI.0b013e3182965d45, ISSN 1525-4135, pages 449 - 455, XP093107466
SEARCH- Gilead, "Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment", Press Release, (20150407), pages 1 - 2, URL: https://s24.q4cdn.com/804398512/files/doc_news/archive/fa11cc2a-1d4e-417e-9419-e7c955a8edef.pdf, (20201207), XP055757389 [I] 1-13 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents